Table 7.

Adjusted Relative Risk of Incident Ischemic Cardiac Death According to Low‐Dose Aspirin Use Among SCCS Participants Stratified by Age, Race/Ethnicity, and Sex Based on Estimations of Multiple Imputed Data

	White	White Women	White Men	Black	Black Women	Black Men
All risk, all ages
Participants, n	19 459	12 462	6997	45 772	26 736	19 036
HR (95% CI)	0.87 (0.68–1.11)	0.73 (0.51–1.04)	1.03 (0.73–1.45)	1.18 (0.99–1.41)	1.05 (0.82–1.35)	1.32 (1.03–1.70)
High CVD risk, all ages
Participants, n	12 769	6496	6273	31 822	14 723	17 099
HR (95% CI)	0.82 (0.63–1.08)	0.72 (0.48–1.07)	0.94 (0.65–1.35)	1.13 (0.94–1.37)	0.97 (0.74–1.28)	1.31 (1.02–1.69)
High CVD risk, 50–69 y
Participants, n	8253	4694	3559	18 031	9889	8142
HR (95% CI)	0.78 (0.56–1.10)	0.72 (0.44–1.16)	0.88 (0.55–1.40)	1.11 (0.88–1.40)	0.94 (0.67–1.33)	1.28 (0.93–1.76)
High CVD risk, 50–59 y
Participants, n	5022	2713	2309	12 786	6570	6216
HR (95% CI)	0.74 (0.48–1.14)	0.64 (0.33–1.25)	0.85 (0.48–1.49)	1.03 (0.75–1.41)	0.93 (0.59–1.49)	1.12 (0.74–1.72)

Relative risk estimated by HR (95% CI) for fatal ischemic cardiac event among those who used and did not use low‐dose aspirin (reference), obtained from stratified Cox proportional hazard models run on multiple imputed data. All models were adjusted by Framingham 10‐year CVD risk category, age at enrollment, sex, race/ethnicity, diabetes mellitus status, and household income, otherwise were not considered as stratification variables. Results are presented for the overall study population (all risk, all ages) and in high‐risk (≥10% CVD risk) participants by race/ethnicity both any age or according to the US Preventive Services Task Force 2016 recommendations on low dose aspirin use for primary prevention of CVD (50–69 and 50–59 years of age). Because estimation samples varied across imputations in high‐risk subgroups, n reflects the number of individuals as in Table 6. CVD indicates cardiovascular disease; HR, hazard ratio; SCCS, Southern Community Cohort Study.